Lineage Cell Therapeutics Inc (LCTX)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Lineage Cell Therapeutics Inc chart...

About the Company

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

CEO

Brian Culley

Exchange

NYSE MKT LLC

Website

http://www.biotimeinc.com/

$8M

Total Revenue

46

Employees

$205M

Market Capitalization

-9.28

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LCTX News

Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results

11d ago, source:

Full Year Net Loss: Full year net loss was $21.5 million, or $0.12 per share, an improvement from a net loss of $26.3 million ...

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11d ago, source: Stockhouse

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter ...

Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements

8d ago, source:

Robert W. Baird analyst Jack Allen maintained a Buy rating on Lineage Therap (LCTX – Research Report) on March 8 and set a price target ...

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

1mon ago, source: Nasdaq

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical ...

Lineage Cell Therapeutics Secures $14M in Direct Offering

1mon ago, source: Hosted on MSN

Lineage Cell Therapeutics, Inc. (LCTX) has released an update to notify the public and investors about an entry into a material definitive agreement. Lineage Cell Therapeutics, Inc. has struck a ...

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

11d ago, source: Seeking Alpha

Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is ...

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

1mon ago, source: Stockhouse

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered ...

Lineage Cell Therapeutics Inc

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...